EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

The Impact of Renin–Angiotensin–Aldosterone System Inhibitors in IgA Nephropathy

Anjay Rastogi iD, Mrinalini Sarkar iD, Kosuke Kawai iD, Gabriel Munoz iD, Lewis Simon iD, Michelle Hwang, Maham Khalid, Connie M Rhee iD

Clinical Journal of the American Society of Nephrology · 2026-10 · 21 (10) · 1701-1709

DOI: 10.2215/cjn.0000001130 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 12.08.2026. Verfasst von Anjay Rastogi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Renin-Angiotensin System, Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Standard-of-care therapy for IgA nephropathy has historically relied on renin–angiotensin–aldosterone system inhibitors. Current treatment goals aim to slow eGFR decline to reduce the risk of ESKD. Analysis of renin–angiotensin–aldosterone system inhibitor therapy alone found an eGFR decline of −4.5 ml/min per 1.73 m 2 per year, which may not limit ESKD risk.

Background

IgA nephropathy is a chronic autoimmune kidney disease characterized by deposition of immune complexes in the glomeruli, leading to inflammation and progressive, irreversible, kidney damage. Patients with IgA nephropathy face a lifetime risk of ESKD, and an associated increase in mortality unless their annual eGFR decline is generally maintained at or below 1 ml/min per 1.73 m 2 . The current standard of care in IgA nephropathy involves supportive CKD therapies, notably renin–angiotensin–aldosterone system inhibitors (RAASi). Importantly, the long-term effectiveness of RAASi in slowing IgA nephropathy disease progression remains uncertain. Meta-analyses of randomized controlled trials with comparable designs offer an opportunity to assess the impact of RAASi therapy on kidney function. Such analyses facilitate outcome comparisons across studies and may generate important evidence and contribute to informed clinical decision making.

Methods

A meta-analysis was conducted using randomized controlled trials that reported the slope of eGFR decline and included one arm receiving maximally tolerated doses of RAASi. The analysis aimed to evaluate the impact of RAASi therapy on kidney function in high-risk patients with IgA nephropathy.

Results

A systematic literature review of four databases returned 171 studies published between January 2006 and November 2024. Of these, ten included a control arm of participants with IgA nephropathy receiving maximized RAASi treatment ( N =1366) and reported eGFR annualized slope decline. Meta-analysis of the pooled data demonstrated a mean annual eGFR slope decline of −4.5 ml/min per 1.73 m 2 (95% confidence interval, −5.3 to −3.8) among participants treated with RAASi therapy alone.

Conclusions

Treatment with maximally tolerated RAASi alone does not sufficiently slow the rate of eGFR decline in high-risk patients with IgA nephropathy, leaving patients at risk of ESKD. These findings underscore the need for disease-modifying therapies capable of effectively preserving kidney function, particularly in this predominantly young patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGARenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHumansRandomized Controlled Trials as TopicGlomerular Filtration RateDisease ProgressionTreatment Outcome

Stichwörter der Autor:innen

GFRIgA nephropathynephropathyrenin–angiotensin system

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Division of Nephrology, Hypertension, and Kidney Transplantation, University of California, Irvine, Orange, California.
  • Nephrology Section, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.

ORCID-Profile: Anjay Rastogi, Mrinalini Sarkar, Kosuke Kawai, Gabriel Munoz, Lewis Simon, Connie M Rhee

Zitieren

APA

Rastogi, A., Sarkar, M., Kawai, K., Munoz, G., Simon, L., Hwang, M., Khalid, M., & Rhee, C. M. (2026). The Impact of Renin–Angiotensin–Aldosterone System Inhibitors in IgA Nephropathy. Clinical Journal of the American Society of Nephrology, 21(10), 1701-1709. https://doi.org/10.2215/cjn.0000001130

Vancouver

Rastogi A, Sarkar M, Kawai K, Munoz G, Simon L, Hwang M, et al. The Impact of Renin–Angiotensin–Aldosterone System Inhibitors in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 2026;21(10):1701-1709. doi:10.2215/cjn.0000001130

BibTeX
@article{Rastogi2026,
  author = {Rastogi, Anjay and Sarkar, Mrinalini and Kawai, Kosuke and Munoz, Gabriel and Simon, Lewis and Hwang, Michelle and Khalid, Maham and Rhee, Connie M},
  title = {The Impact of Renin–Angiotensin–Aldosterone System Inhibitors in IgA Nephropathy},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {10},
  pages = {1701--1709},
  doi = {10.2215/cjn.0000001130}
}
Kostenlos starten →